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The proteasome core interacts with different activators and incorporates alternate active subunits, thereby
generating a diverse pool of subspecies. The enzymatic properties of these different species are not well
understood. In this issue of Chemistry & Biology, Raule and colleagues present a comprehensive enzymatic
characterization of immunoproteasome complexes associated with the proteasome activator PA28.The heterogeneity of proteasome popula-
tions in mammalian cells originates from
two features. The constitutive active site
subunits of the proteolytic core can be
replaced by orthologs dependent on the
cellular context, and the proteasome
core can interact with different activators.
Previous reports suggest that both events
change either the specificity or activity of
the proteasome. The detailed mecha-
nistic analysis by Raule et al. (2014) in
this issue of Chemistry & Biology extends
these earlier reports and represents an
important achievement in understanding
the mechanistic consequences of PA28
binding to immunoproteasomes.
Proteasomes are critical compo-
nents of the immune response as this
protease generates antigenic peptides
presented by major histocompatibility
complex (MHC) class I molecules. In
cells exposed to cytokines such as inter-
feron-g, the three constitutive active b
subunits (b1, b2, and b5) in the catalytic
chamber are replaced by the alterna-
tive and homologous immunosubunits
(b1i, b2i, and b5i) (Kniepert and Groettrup,
2014). 26S immunoproteasomes exhibit a
reduction in the proteasomal caspase-like
activity and release 2–4 times more spe-
cific N-extended immunodominant pep-
tides as compared to constitutive 26S
proteasomes (Kniepert and Groettrup,
2014).
Stimulation of cells with cytokines also
induces the expression of PA28 a and b
subunits. They form a heteroheptameric
ring that can attach to the ends of the
20S core particle. The increased expres-
sion in the presence of cytokines
suggested that PA28ab might play a role
in proteasome-mediated generation of
MHC class I ligands, yet PA28ab deficientmice exhibit only mild defects in antigen
processing or immune response (Murata
et al., 2001). Thus, the precise cellular
functions of this class of activators are still
under investigation. Previous work
demonstrated that PA28ab stimulates
the hydrolysis of short peptides in an
ATP-independent manner (Ma et al.,
1992). It was suggested that PA28ab acti-
vates the peptidase activity of the 20S
proteasomes by accelerating peptide
uptake or product release in vitro. It was
also found that after PA28ab binding, pro-
teasomes favored coordinate double
cleavage when short peptides were used
as substrates (Dick et al., 1996). Upon
association with singly capped 26S
immunoproteasomes, PA28ab generates
a pattern of peptides different from those
produced by 26S immunoproteasomes
(Cascio et al., 2002). These data indicated
that PA28ab might change the cleavage
mechanism of 20S proteasomes or
immunoproteasomes.
A crystal structure of PA26, the PA28
ortholog in Tryponasoma brucei, in a com-
plex with the yeast proteasome core
revealed that attachment of PA26 opens
the normally closed gate in the 20S a
ring, through which substrates enter
the proteolytic chamber (Whitby et al.,
2000). The open gate could potentially
reduce the retention time of degradation
products in the catalytic chamber and
thus may facilitate the exit of a larger pep-
tide fragment. Therefore, PA28 activators
were predicted to promote the release of
longer peptide products from the proteo-
lytic core particle and thus increase the
generation of peptides suitable for MHC
class I antigen presentation.
The results presented by Raule et al.
(2014) provide important new insightsChemistry & Biology 21, April 24, 2014into the impact of PA28ab on proteasomal
degradation. The study shows for the first
time that PA28ab activators can mediate
the degradation of small unstructured
proteins. This finding was unexpected,
because an early study aimed at charac-
terizing the properties of PA28ab reported
that the activator did not stimulate the
degradation of proteins (Ma et al., 1992).
This discrepancy could potentially be ex-
plained by improved purification proce-
dures in the new study. The ability of
PA28ab to stimulate the degradation of
small unstructured proteins is shared
with other noncanonical proteasome acti-
vators such as PA28g (Li et al., 2006) and
PA200/Blm10 (Dange et al., 2011). Char-
acterizing the impact of PA28ab on immu-
noproteasomal degradation of casein and
insulin-like growth factor (IGF)-1, Raule
et al. (2014) found that the rate of cleavage
product generation was enhanced in the
presence of PA28ab. Surprisingly, how-
ever, the rate of actual protein clearance
remained unaltered. Mechanistically, this
implies that PA28ab has no effect on
substrate uptake, but it affects the fate
of the substrate once it has entered the
catalytic chamber of the proteasome or
during the release of cleavage products.
Given the small sample of substrates
investigated so far, it remains to be
determined whether unaffected substrate
uptake in the presence of PA28ab
is unique to casein and IGF-1 or is a gen-
eral characteristic of PA28ab-proteasome
complexes.
To obtain further mechanistic insights
into PA28ab-mediated degradation of
proteasome substrates, the authors
investigated the peptides produced by
immunoproteasomes in the absence












Figure 1. The Impact of PA28ab on Proteasome-Mediated Protein Degradation
(A) The 20S immunoproteasome degrades unstructured nonubiquitinated proteins. Light blue, a subunit
ring; pink, b subunit ring.
(B) PA28 induces gate opening and most likely allosteric changes in the proteolytic cavity of the 20S to
either facilitate double cleavage or block the release of longer peptides, resulting in an elevated number
of shorter peptides generated. The frequency of caspase-like cleavage events increases in the presence
of PA28 (indicated by red negative charges). The structural changes in the 20S barrel are indicated by a
darker shading of the a and b rings. Green, PA28.
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produce peptides between 1–26 resi-
dues. These findings are interesting,
because previous reports suggested that
the proteasome does not generate very
short peptides. The association of the
19S cap with the 20S core led to a ten
times increased hydrolysis rate. Capping
the core with PA28ab led to an overall
decrease in peptide size (Figure 1). The
authors have ruled out the possibility
that the already-released fragments
reenter into the catalytic chamber of the
immunoproteasomes in the presence of
PA28ab by performing the experiments
with an excess of substrate and analyzing
the products under conditions where
only 10% of the substrate had been
consumed. The data support a model in
which PA28ab might promote coopera-
tive binding of substrate molecules to
two cleavage sites, leading to a concerted
dual-cleavage mechanism as proposed
by Dick et al. (1996). Additionally,
PA28ab might facilitate the release of
shorter products, but it hinders the exit
of longer peptides as suggested by
kinetic modeling studies.
Next, the authors identified the pep-
tides generated by the different immuno-
proteasome complexes by tandem mass
spectrometry. The different proteasomal
subcomplexes generated quantitatively
and qualitatively very different sets of
peptides. A general characteristic of436 Chemistry & Biology 21, April 24, 2014 ªimmunoproteasomes is a decrease
in caspase-like activity (Kniepert and
Groettrup, 2014). Surprisingly, Raule
et al. (2014) found that the peptides
generated by immunoproteasomes in
the presence of PA28ab revealed an
increase in caspase-like cleavage events
(Figure 1B) and hydrophilicity. Although
crystallographic data did not reveal
changes in the 20S active site topology
in the presence of PA26 (Whitby et al.,
2000), the current data provide evidence
for allosteric changes within the catalytic
chamber of the proteasome core upon
activator binding. This model is in agree-
ment with a previous report employing
solution NMR spectroscopy to study
PA28ab binding to the proteasome core
(Ruschak and Kay, 2012). The report re-
vealed long range structural changes
affecting the active sites in the protea-
some core of T. acidophilum upon PA26
binding. Alternatively, PA28ab could
impact the efflux of peptides.
A surprising additional conclusion from
this study is that PA28 promotes mostly
the generation of peptides that are not
suited for MHC class I antigen presenta-
tion. These findings are contrary to the
expected role of PA28 in the generation
of antigenic peptides. Potentially, PA28
might promote the generation and pro-
cessing of epitopes not by enhancing
the fraction of peptides, but by selectively
stimulating the generation of specific2014 Elsevier Ltd All rights reservedMHC class I epitopes. Alternatively, PA28
might serve as a regulator to blunt a
potentially excessive generation of anti-
genic peptides derived from cytoplasmic
proteins that could result in autoimmune
diseases. Finally, recent data argue for
an immune-response independent func-
tion of PA28 in the degradation of oxidized
proteins (Pickering et al., 2010).
Cumulatively, the study by Raule et al.
(2014) reveals novel biochemical informa-
tion on the impact of PA28ab activators
on the enzymatic properties of protea-
somes that clarify and expand previous
models. They demonstrate that this
activator mediates the degradation of
unstructured proteins and most likely
induces allosteric changes within the
catalytic chamber of the proteasome.
The results additionally indicate that
the primary function of PA28ab activa-
tors might not be related to antigen
presentation.REFERENCES
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